Close Menu
Global News HQ
    What's Hot

    Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000

    July 29, 2025

    I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’

    July 29, 2025

    The first company to complete a fully successful lunar landing is going public

    July 29, 2025
    Recent Posts
    • Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000
    • I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’
    • The first company to complete a fully successful lunar landing is going public
    • We Swept Up 3 Weeks’ Worth of Debris to Find the 7 Best Brooms 
    • Client Challenge
    Facebook X (Twitter) Instagram YouTube TikTok
    Trending
    • Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000
    • I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’
    • The first company to complete a fully successful lunar landing is going public
    • We Swept Up 3 Weeks’ Worth of Debris to Find the 7 Best Brooms 
    • Client Challenge
    • Whistle pet trackers are shutting down next month
    • Chase Sapphire Preferred vs. Amex Gold: Which card is best? – The Points Guy
    • Interactive Brokers weighs launching customer stablecoin to power 24/7 funding
    Global News HQ
    • Technology & Gadgets
    • Travel & Tourism (Luxury)
    • Health & Wellness (Specialized)
    • Home Improvement & Remodeling
    • Luxury Goods & Services
    • Home
    • Finance & Investment
    • Insurance
    • Legal
    • Real Estate
    • More
      • Cryptocurrency & Blockchain
      • E-commerce & Retail
      • Business & Entrepreneurship
      • Automotive (Car Deals & Maintenance)
    Global News HQ
    Home - Health & Wellness (Specialized) - FDA Approves New Preventive Drug for Hereditary Angioedema (HAE)
    Health & Wellness (Specialized)

    FDA Approves New Preventive Drug for Hereditary Angioedema (HAE)

    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    FDA Approves New Preventive Drug for Hereditary Angioedema (HAE)
    Share
    Facebook Twitter LinkedIn Pinterest Email


    People with hereditary angioedema (HAE), a rare genetic disorder, may experience episodes of debilitating, unpredictable, and potentially life-threatening swelling in the abdomen, larynx (voice box), face, and extremities.

    But there is a new, first-of-its-kind drug to prevent these attacks: The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab), a once-monthly medicine injected under the skin, for adults and children 12 and older.

    Unlike older drugs for hereditary angioedema designed to treat swelling once it happens, Andembry was created to prevent attacks from happening in the first place. The new drug blocks a protein called activated factor 12 (FXIIa) that is responsible for setting off a chain reaction in the body that leads to these episodes.

    “People with HAE now have another choice for lessening the burden associated with this lifelong condition and realizing the community’s shared goal of experiencing life to the fullest,” said Anthony J. Castaldo, CEO of the advocacy nonprofit U.S. Hereditary Angioedema Association, in a statement.

    What Causes Hereditary Angioedema?

    People with hereditary angioedema experience sudden swelling because they lack a protein in their blood known as C1 inhibitor (C1-Inh) that’s responsible for controlling inflammation and regulating immune responses, says Bruce Ritchie, MD, a professor of hematology at the University of Alberta in Canada.

    “With reduced amounts of this C1-Inh protein, patients can experience unpredictable episodes of swelling anywhere on their body, often precipitated by stress or small traumas,” Dr. Ritchie says. “These swellings can range from merely troublesome to life-threatening if they occur near the patient’s breathing passage or airway.”

    Traditional treatments for hereditary angioedema have involved replacing C1-Inh using infusions of this protein from donor blood, Ritchie says. Patients can use these infusions to treat attacks, and they can also give themselves injections under the skin up to three times a week to help prevent attacks, Ritchie says.

    One key advantage of Andembry is that its preventive effects may last for two to four weeks, instead of just a handful of days, Ritchie says.

    “Garadacimab has a longer half life with excellent efficacy and targets a different pathway, factor 12a,” says Jonathan Bernstein, MD, a professor at the University of Cincinnati College of Medicine who worked on research studies of garadacimab for hereditary angioedema. Plus, he says, “It has very few side effects.”

    People Taking Andembry Had Less Than 1 HAE Swelling Attack per Month on Average

    In a late-stage clinical trial, researchers randomly assigned 39 people with hereditary angioedema to take garadacimab and 25 people to take placebo injections for six months. During the study period, people taking Andembry had an average of 0.27 swelling attacks per month, compared with an average of 2.01 monthly attacks for people taking the placebo.

    The most common treatment side effects were upper-respiratory tract infections, colds, headaches, and stomach pain. About 14 percent of people taking Andembry reported injection site reactions, including bruising, discoloration, itching, and rash.

    These are better outcomes than patients can get with C1-Inh infusions from donor blood, Ritchie says. Many people who routinely use C1-Inh infusions to prevent swelling attacks may switch to garadacimab, Ritchie predicts.

    “The approval of garadacimab should hopefully lead to availability to patients with more severe hereditary angioedema, who use C1-Inh [for attack prevention] or frequently on demand,” Ritchie says.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleInsurance industry under direct attack by hacker group
    Next Article Shoppers Say These $50 Sneakers Are ‘Just as Comfortable’ as $180 Hokas—and They Even Help Relieve Plantar Fasciitis

    Related Posts

    I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’

    July 29, 2025

    NIH researchers develop AI agent that improves accuracy of gene set analysis by leveraging expert-curated databases

    July 28, 2025

    What Your Sign Needs To Know For This Summer’s Mercury Retrograde

    July 28, 2025

    These Neuroprotective Nutrients Can Help Lower Your Dementia Risk

    July 27, 2025
    Leave A Reply Cancel Reply

    ads
    Don't Miss
    Cryptocurrency & Blockchain
    3 Mins Read

    Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000

    Yesterday, Bitcoin (BTC) once again faced rejection around the $120,000 resistance level after briefly reaching…

    I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’

    July 29, 2025

    The first company to complete a fully successful lunar landing is going public

    July 29, 2025

    We Swept Up 3 Weeks’ Worth of Debris to Find the 7 Best Brooms 

    July 29, 2025
    Top
    Cryptocurrency & Blockchain
    3 Mins Read

    Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000

    Yesterday, Bitcoin (BTC) once again faced rejection around the $120,000 resistance level after briefly reaching…

    I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’

    July 29, 2025

    The first company to complete a fully successful lunar landing is going public

    July 29, 2025
    Our Picks
    Cryptocurrency & Blockchain
    3 Mins Read

    Bitcoin Rejected At $120,000: Binance Whale Inflows Suggest Possible Drop To $110,000

    Yesterday, Bitcoin (BTC) once again faced rejection around the $120,000 resistance level after briefly reaching…

    Health & Wellness (Specialized)
    3 Mins Read

    I Swear By the $10 Pain Relief Gel Shoppers Say Makes Aches and Soreness ‘Disappear’

    Staying active is incredibly rewarding. But let’s face it: It often comes with a good…

    Pages
    • About Us
    • Contact Us
    • Disclaimer
    • Homepage
    • Privacy Policy
    Facebook X (Twitter) Instagram YouTube TikTok
    • Home
    © 2025 Global News HQ .

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version